FASN and alcoholic fatty liver disease: Data from phase I clinical trial corroborate that TVB‐2640, a FASN inhibitor, restrains the uptrend of hepatic de novo lipogenesis and thus emerges as a novel therapeutic avenue for non‐alcoholic fatty liver disease.